◆ 会议时间：2023年10月13-14日
◆ 会议地点：美国 坦佩（Tempe）

◆ 会议简介：

2023年第20届国际胃肠道肿瘤学会(ISGIO)年会将于2023年10月13-14日在美国坦佩举行。ISGIO胃肠道肿瘤学大会是国际胃肠肿瘤学会(ISGIO)的官方年度会议，大会将展示和讨论胃肠道癌症研究领域的最新进展，以及探讨与胃肠道癌患者护理相关的关键议题。

国际胃肠道肿瘤学会(ISGIO)是全球第一个致力于胃肠道肿瘤研究与教育的非营利性组织，现在全球拥有1500多名成员。ISGIO的使命是建立一个交流胃肠道肿瘤学前沿研究和实践问题的权威论坛；鼓励年轻的研究人员参与胃肠道肿瘤研究；促进全球GI肿瘤的研究和教育；宣促进新的GI肿瘤相关知识和发现的及时交流和传播；在全球范围内促进GI肿瘤的卓越治疗；减轻胃肠道癌症的社会负担；等等。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.

ISGIO 2023 - 20th Annual Meeting of the International Society of Gastrointestinal Oncology
Date: October 13, 2023 - October 14, 2023
Venue: Tempe Mission Palms Hotel, Tempe, AZ, USA

Physicians’ Education Resource®, LLC (PER®), is pleased to present the 2023 Gastrointestinal Oncology Conference, the 20th Annual Meeting of the International Society of Gastrointestinal Oncology® (ISGIO), a 2-day, multidisciplinary educational conference dedicated to presenting and discussing the latest advances in the broad field of gastrointestinal (GI) cancer research, as well as critical issues relevant to the care of persons with GI cancer. 

GI malignancies are often difficult to treat because of their heterogeneity. The optimal management of these tumors often requires a high level of multidisciplinary cooperation and the use of multimodality treatment regimens.

This highly engaging conference brings together world-renowned experts from different disciplines to educate clinicians using a combination of case-based learning, debates, panel discussions, and didactic segments. Throughout the educational sessions, attendees will have numerous opportunities to interact with the presenting faculty.

The learning objectives of this program are:

• Describe current standards of care for treatment of gastrointestinal (GI) malignancies
• Analyze clinical trial data that may impact treatment decision-making in GI oncology
• Implement multimodal approaches to the treatment of GI malignancies

The target audience for this activity is directed toward oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in GI oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.

摘要提交-Call for Poster Abstracts：

Deadline for submission is July 14, 2023.

点此提交摘要>>>Submit Abstract>>>

All poster abstract submissions must be made electronically through the conference’s online abstract submission system.

Your abstract should be a short description of your work and contain all the elements necessary to define your goals and results to the reader. Authors will be required to disclose all financial relationships through the online system, to ensure quality and unbiased presentations. The formal poster session is not designated for credit.

Share your research or best practices with your peers. Categories of submission include the following:

• Colorectal cancer
• Esophageal/gastric cancer
• Hepatobiliary cancer
• Pancreatic cancer
• Neuroendocrine tumors
• Other GI-related oncology

The program chairs will evaluate the scientific quality of the submitted abstracts on the basis of the following criteria: novelty of the research, significance of the findings, and clarity. Incomplete abstracts will not be reviewed. Please note that we will consider case series of more than 5 reports, but we are not accepting case series of <5 patients and single-patient case reports.

Notification of acceptance or regret will be delivered via email to the presenter(s) of each poster abstract by August 11, 2023. Please note that an author is required to be present during the poster session.

If accepted for presentation, abstracts and posters will be available for viewing online on the 2023 conference website during and after the conference. The posters will be displayed for the length of the conference. The presentation at the 20th Annual Meeting of the International Society of Gastrointestinal Oncology® should reflect the submitted abstract, abstract title, authorship, and content.

• This year, selected accepted original abstracts at the 20th Annual Meeting of the International Society of Gastrointestinal Oncology® will be published in a print supplement to the Oncology® journal. All accepted abstracts will be published after the conference in an online-only supplement to Oncology®, on the journal website. Previously presented (ie, encore) abstracts will not be published in Oncology®; they will only be displayed in connection with the meeting (eg, online program).
•  If an author does not want the abstract published after the meeting, they must indicate that during submission.
• The organizers reserve the right not to publish abstracts that do not fit into any of the review categories; abstracts that inappropriately promote commercial interests; abstracts that are judged unethical, poorly written, or scientifically unsound; or abstracts considered inappropriate for publication for other reasons as determined by the program committee.

All presenters must register to attend the 20th Annual Meeting of the International Society of Gastrointestinal Oncology®

Submission Process

• Complete the abstract template provided on the 20th Annual Meeting of the International Society of Gastrointestinal Oncology® website.
• Limit is 2500 characters (abstract body, including spaces and 1 table).
  

Components of the Abstract Body Limit: 2500 words (1 table is allowed)

Abstracts of Clinical Trials With Results to Be Presented

• Background/Significance: What was the problem, and why was it  important? What knowledge are you building on? What was the intent or  goal of the study? What did you want to learn?
• Materials and Methods: What was the trial design? What was the sample?  What instruments were used? How were data collected and analyzed?
• Results: What were the findings?
• Conclusions: What do the findings mean?

Abstracts of Clinical Trials in Progress (ie, results not yet available)

• Background/Significance: What is the problem, and why is it important?  What knowledge are you building on? What are the objectives of the  study? What do you want to learn?
• Design and Methods: What is the trial design? What is the study  population (including inclusion and exclusion criteria)? What is the  statistical design? What are the study end points?
• Status: What is the current status of the trial (eg, enrollment  status, participating study centers, anticipated completion date)?

Abstract Questions

Please submit any questions pertaining to abstract submissions to abstracts@gotoper.com using the subject line “ISGIO Abstract QUESTION.”

Author Consent and Waiver of Claims

• Each abstract author agrees and certifies that he or she:
• Waives any and all claims against Physicians' Education Resource®, LLC (PER®), sponsor of the 20th Annual Meeting of the International Society of Gastrointestinal Oncology®,  and any review arising out of or relating to the abstract submission and review process, including but not limited to peer review and the  grading of abstracts.

Answers to Frequently Asked Questions

• Abstracts in the following categories will also be considered for presentation:
• Basic science (preclinical research), pharmacokinetics/pharmacodynamics, and health economic outcomes research
• Case series of ≥5 patients (case series of <5 patients and single-patient case reports are not accepted)
• Encore presentations (abstract and poster must indicate where originally presented)
• Late-breaking abstracts
• Literature reviews
• Research abstracts funded by for-profit organizations, including biotech and pharmaceutical
• Trials in progress:
• Trial must be open to accrual
• Abstracts/posters for the “Trials in Progress” category cannot include end point data from the trial. If end point data are to be presented, please submit under the “Abstracts of Clinical Trials With Results to Be Presented” category.
• Abstracts are currently accepted only for poster presentation, not oral presentation
• Abstracts are not published, but are posted to the attendee eSyllabus
• Pharmaceutical industry authors are allowed to present abstracts
• A non-named author can present a poster if written permission to do so is provided by the lead author

 Abstract Format 

• The title of the abstract should be brief and objectively describe the study. Do not use nonstandard abbreviations and commercial names (use generic names only). Use title case and capitalize all nouns, verbs, adverbs, and conjunctions of 4 letters or more. Do not capitalize a coordinating conjunction, an article, or a preposition of 3 or fewer letters, except when it is the first or last word in a title. Keep letters lowercase if the lowercase letters have a specific meaning, such as pH or mL. Do not put a period at the end of the title.
• No more than 15 authors can be listed with institutional affiliations, cities, and countries only. Mailing addresses and academic degrees should not be mentioned in the author's list. For cooperative study groups, you may give the name of the group instead of individual institutional affiliations or include the name of the group in the title of the abstract.
• First Author (Presenting Author): The name, institution, telephone number, and email address of the First Author are required. The First Author (Presenting Author) will receive all future correspondence from PER®.
• Abstracts should be structured in such a way as to include the following sections: 
• Abstracts of Clinical Trials With Results to Be Presented (4 sections) 

1. Background: an introductory sentence indicating the purpose of the study 
2. Material and Methods: a brief description of pertinent experimental procedures 
3. Results: a summary of the results of the research 
4. Conclusions: a statement of the main conclusions   

• Abstracts of Clinical Trials in Progress (ie, results not yet available; 3 sections)
• Background: an introductory sentence indicating the purpose of the study
• Design and Methods: a brief description of pertinent experimental procedures
• Status: a summary of the status of the study
• Abstracts  should not exceed 2500 characters (body of the abstract, including  spaces and table).
• Only 1 data table is  permitted in the body of the abstract. Illustrations and/or figures are not allowed and will be deleted if submitted.
• Standard abbreviations may be used and must be spelled out and defined at the first      use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lowercase. Commercial names may be included in the abstract text in parentheses, directly following the generic name at first use. For example, "generic (Commercial).” Do not use trademark symbols.
• Abstracts cannot be revised once submitted.
• The abstract must be submitted in English.

*RESIDENTS & FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.

**INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

For registration assistance, please email info@gotoper.com, or call +1-(888)-949-0045 or +1-(609)-378-3701.

A cancellation fee of 25% will be assessed on refunds requested prior to July 13, 2023, and a 50% fee on refunds requested on July 13, 2023, through September 13, 2023. No refunds will be made after September 13, 2023. . There is no charge for substitution. Substitutions can only be applied to the same conference, and only 2 substitutions will be honored.

In the event of a meeting cancellation, full refunds will be processed within 30 days of the cancellation date.

◆ 参会对象：肿瘤学家/医师和肿瘤学亚专业的从业者，以及对胃肠道肿瘤学感兴趣的外科医生、放射科医生、普通科学家、年轻调查员、护士和药剂师，以及其他对治疗这些恶性肿瘤感兴趣的医疗保健专业人员。